Charles Andrews
Pulmonary Disease · San Antonio, TXNPI 1467459578
Payments from drug & device makers
Across 2,423 payments — averaging $7007.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7.1M
- GSK$3M
- Merck$2.6M
- Modernatx, Inc.$1.9M
- Boehringer Ingelheim$934K
- Biontech SE$477K
- plus $987K from 17 others
Across 2 payments — averaging $940.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2K
- Teva Pharmaceuticals USA, Inc.$61
What the payments were for
- Consulting fees$5,13546%
- Travel & lodging$3,58432%
- Food & beverage$2,37321%
- Education$571%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 416 | $7,116,867 |
| GSK | 723 | $2,957,904 |
| Merck | 313 | $2,648,222 |
| Modernatx, Inc. | 605 | $1,858,457 |
| Boehringer Ingelheim | 46 | $934,161 |
| Biontech SE | 77 | $476,971 |
| Sanofi Pasteur Inc. | 22 | $269,855 |
| Hikma Pharmaceuticals USA | 7 | $256,670 |
| Boehringer Ingelheim International GmbH | 46 | $163,757 |
| AstraZeneca | 4 | $92,342 |
| Teva Pharmaceuticals USA, Inc. | 21 | $69,827 |
| Regeneron | 1 | $52,069 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 55 | $28,689 |
| Noven Pharmaceuticals, Inc. | 3 | $22,730 |
| Mylan Specialty L.p. | 7 | $9,168 |
| Boehringer Ingelheim France S.a.s. | 61 | $8,896 |
| Sanofi US Services Inc. | 1 | $8,400 |
| Glenmark Therapeutics Inc. | 1 | $1,683 |
| Bayer Healthcare LLC | 1 | $1,439 |
| Boehringer Ingelheim Limited | 9 | $957 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $487 |
| Alk-abello, Inc | 1 | $117 |
| AbbVie(2 entities) | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mupirocin Cream$1,683
- Vitrakvi$1,439
- OFEV$404
- V114$247
- Yupelri$125
- TRELEGY ELLIPTA$123
- Odactra$117
- Ragwitek$117
- Grastek$117
How this compares
$16,979,711 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in San Antonio
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
- John HolcombSan Antonio$1.7M
- David MarksSan Antonio$1.3M
- Anoop NambiarSan Antonio$840K
- Rodolfo Estrada AnzuetoSan Antonio$324K
- Ali AbediSan Antonio$269K
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.